학술논문
Effect of INaL blockers in transgenic mouse models of hypertrophic cardiomyopathy is mutation-specific: severe Ca2+ handling abnormalities as requisite for Ranolazine and GS967 to exert a full efficacy effect
Document Type
Abstract
Author
Source
In Vascular Pharmacology September 2020 132
Subject
Language
ISSN
1537-1891